Oppenheimer Issues Pessimistic Forecast for InflaRx (NASDAQ:IFRX) Stock Price

InflaRx (NASDAQ:IFRX - Get Free Report) had its price objective lowered by equities research analysts at Oppenheimer from $6.00 to $3.00 in a report issued on Thursday,Benzinga reports. The firm currently has an "outperform" rating on the stock. Oppenheimer's price target would suggest a potential upside of 274.06% from the stock's current price.

IFRX has been the topic of a number of other research reports. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 target price on shares of InflaRx in a research report on Friday, March 21st. Raymond James downgraded shares of InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 target price for the company. in a report on Thursday. Guggenheim upped their price target on InflaRx from $7.00 to $10.00 and gave the stock a "buy" rating in a research note on Wednesday, March 26th. Finally, Cantor Fitzgerald started coverage on InflaRx in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, InflaRx has a consensus rating of "Buy" and an average price target of $6.60.

InflaRx Stock Down 0.1%

Shares of InflaRx stock traded down $0.00 during mid-day trading on Thursday, hitting $0.80. The stock had a trading volume of 532,999 shares, compared to its average volume of 271,980. The firm has a 50-day moving average of $1.33 and a two-hundred day moving average of $1.82. The firm has a market cap of $53.84 million, a P/E ratio of -0.74 and a beta of 1.57. InflaRx has a 12-month low of $0.71 and a 12-month high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. InflaRx had a negative return on equity of 65.98% and a negative net margin of 33,362.70%. The company had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. Sell-side analysts expect that InflaRx will post -1.04 earnings per share for the current year.

Institutional Investors Weigh In On InflaRx

A number of hedge funds have recently added to or reduced their stakes in IFRX. Two Sigma Securities LLC acquired a new position in shares of InflaRx in the fourth quarter worth $28,000. Cubist Systematic Strategies LLC grew its stake in InflaRx by 33.9% during the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock worth $31,000 after purchasing an additional 7,616 shares in the last quarter. XTX Topco Ltd purchased a new stake in InflaRx during the 1st quarter worth about $38,000. Walleye Capital LLC acquired a new stake in InflaRx in the 4th quarter valued at about $51,000. Finally, Geode Capital Management LLC boosted its stake in shares of InflaRx by 32.8% in the 4th quarter. Geode Capital Management LLC now owns 48,136 shares of the company's stock valued at $119,000 after buying an additional 11,900 shares during the period. 42.39% of the stock is currently owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.